Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02234115
Recruitment Status : Completed
First Posted : September 9, 2014
Results First Posted : April 13, 2018
Last Update Posted : March 5, 2019
Information provided by (Responsible Party):
Foresee Pharmaceuticals Co., Ltd.

Brief Summary:
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: Leuprolide Mesylate Phase 3

Detailed Description:
This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was established to provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety. If safety is established, the remainder of the subjects will be entered into the clinical study (i.e., Part II). All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 137 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma
Study Start Date : August 2014
Actual Primary Completion Date : August 30, 2016
Actual Study Completion Date : January 5, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Leuprolide Mesylate 50mg
All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
Drug: Leuprolide Mesylate
Subcutaneous injection of 50mg Leuprolide Mesylate

Primary Outcome Measures :
  1. Efficacy of Leuprolide Mesylate (LMIS 50mg) [ Time Frame: baseline to 28 days, 28 days to 336 days ]
    The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).

Secondary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: 336 days ]
    Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males aged ≥ 18 years old
  2. Males with histologically confirmed carcinoma of the prostate
  3. Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
  4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit
  5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2
  6. Life expectancy of at least 18 months
  7. Laboratory values

    • Absolute neutrophil count ≥ 1,500 cells/µL
    • Platelets ≥ 100,000 cells/µL
    • Hemoglobin ≥ 10 gm/dL
    • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
    • AST (SGOT) ≤ 2.5 × ULN
    • ALT (SGPT) ≤ 2.5 × ULN
    • Serum creatinine ≤ 1.5 mg/dL
    • Lipid profile within acceptable range according to investigator's judgment
    • HgbA1c within acceptable range according to investigator's judgment
    • Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
    • Serum glucose within acceptable range according to investigator's judgement
    • Urinalysis within normal range according to the investigator's judgment
  8. Agree to use male contraceptive methods during study trial
  9. Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
  10. All aspects of the protocol explained and written informed consent obtained

Exclusion Criteria:

  • Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
  • Receipt of any vaccination (including influenza) within 4 weeks of Baseline
  • History of blood donation within 2 months of Baseline
  • History of anaphylaxis to any LH-RH analogues
  • Receipt of any LHRH suppressive therapy within 6 months of Baseline
  • Major surgery, including any prostatic surgery, within 4 weeks of Baseline
  • History and concomitant clinical and radiographic evidence of central nervous system/spinal cord metastases. Subjects at risk for spinal cord compression will be excluded.
  • Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
  • History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
  • History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
  • Clinically significant abnormal ECG and/or history of clinically significant cardiovascular disease as judged by the investigator
  • History of drug and/or alcohol abuse within 6 months of Baseline
  • Contraindication to leuprolide or an LHRH agonist as indicated on package labeling
  • Use of 5-alpha reductase inhibitor within the last 6 months of Baseline
  • History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed
  • Use of systemic corticosteroids at a dose >10 mg/d or anti-androgens
  • Use of any investigational agent within 4 weeks of Baseline
  • Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for those listed in the permitted Concomitant Treatment section.
  • Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02234115

Show Show 29 study locations
Sponsors and Collaborators
Foresee Pharmaceuticals Co., Ltd.
Layout table for investigator information
Study Director: John Mao, PhD Foresee Pharmaceuticals Co., Ltd.
Layout table for additonal information
Responsible Party: Foresee Pharmaceuticals Co., Ltd. Identifier: NCT02234115    
Other Study ID Numbers: FP01C-13-001
2013-001790-25 ( EudraCT Number )
First Posted: September 9, 2014    Key Record Dates
Results First Posted: April 13, 2018
Last Update Posted: March 5, 2019
Last Verified: February 2019
Keywords provided by Foresee Pharmaceuticals Co., Ltd.:
Prostate Neoplasm Cancer Carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents